INT301935

Context Info Confidence 0.13 First Reported 2010 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 6 Disease Relevance 4.40 Pain Relevance 0.27

cytosol (UCK2) small molecule metabolic process (UCK2) kinase activity (UCK2) cellular_component (UCK2)

Anatomy Link Frequency lower limb 2 FaDu 1 HeLa 1 UCK2 (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammation 8 98.88 Multiple sclerosis 20 96.60 peripheral neuropathy 16 77.56 cINOD 4 11.84 COX-2 inhibitor 24 5.00 Migraine 8 5.00 headache 6 5.00 COX2 4 5.00 cytokine 4 5.00 Spinal cord 2 5.00

Disease Link Frequency Relevance Heat Spasticity 14 100.00 INFLAMMATION 12 98.88 Cancer 248 98.44 Demyelinating Disease 24 96.60 Spastic Paraparesis 8 95.60 Metastasis 52 94.32 Carcinoma 48 92.88 Mitochondrial Disorders 8 85.44 Chronic Progressive External Ophthalmoplegia 22 79.40 Peripheral Neuropathy 16 77.56

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In the two probands presenting with progressive lower limb spasticity (UK-3 and UK-5), no underlying metabolic, inflammatory or compressive causes were found despite extensive investigations over several years.

Gene_expression (presenting) of UK-5 in lower limb associated with spasticity and inflammation

1) Confidence 0.13 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 1.07 Pain Relevance 0.14

In the two probands presenting with progressive lower limb spasticity (UK-3 and UK-5), no underlying metabolic, inflammatory or compressive causes were found despite extensive investigations over several years.

Gene_expression (presenting) of UK-3 in lower limb associated with spasticity and inflammation

2) Confidence 0.13 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 1.07 Pain Relevance 0.14

FaDu and HeLa cells were treated with WX-UK1 alone or a combination of WX-UK1, Galardin®, and Celecoxib®, and plated on matrigel invasion chambers composed of 6-well inlays with 8 ?

Gene_expression (treated) of WX-UK1 in FaDu

3) Confidence 0.04 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.41 Pain Relevance 0

The in vivo anti-metastatic and anti-proliferative activity of the synthetic uPA inhibitor WK-UK1 has been demonstrated in various animal tumour models.

Gene_expression (synthetic) of WK-UK1 associated with cancer

4) Confidence 0.04 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 1.04 Pain Relevance 0

l medium (0.1% FCS) was added into inserts for 24 hours, as was WX-UK1 (Wilex, Munich, Germany) at a concentration of 1.0 ?

Gene_expression (added) of WX-UK1

5) Confidence 0.04 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.40 Pain Relevance 0

FaDu and HeLa cells were treated with WX-UK1 alone or a combination of WX-UK1, Galardin®, and Celecoxib®, and plated on matrigel invasion chambers composed of 6-well inlays with 8 ?

Gene_expression (treated) of WX-UK1 in HeLa

6) Confidence 0.01 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.